NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Amphivena Therapeutics

Amphivena Therapeutics

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://rakhoitv68x.io/

Last Round

Series C

Sep 24, 2019

Total Funding Raised

$95.5M

Company Overview

Amphivena Therapeutics is a clinical-stage immuno-oncology company that develops bivalent T-cell engagers for the treatment of hematologic and solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immuno-oncologybispecific T-cell engagerbiotechcancer immunotherapyacute myeloid leukemiaAMLmyelodysplastic syndromesMDSdrug discoveryclinical-stage biotechmyeloid-derived suppressor cellsMDSCbiologicstherapeutic platformdrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Amphivena Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Amphivena Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Amphivena Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CSep 24, 2019
Series BJun 26, 2017
Series AJul 1, 2013

Amphivena Therapeutics Investors

Notable investors and investment history

Amphivena Therapeutics investors
InvestorRounds
MPM CapitalSeries C, Series A
KorysSeries C
Kaitai CapitalSeries C
Aeris Capital ManagementSeries A, Series B
+ND CapitalSeries C
MPM BioImpactSeries C, Series A, Series B
OrbiMedSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 24, 2019

    $62M round led by +ND Capital.

Amphivena Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Amphivena Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Amphivena Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range1
Year Founded2012
Last FundingSep 24, 2019

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.